by Raymond Tel | Jun 8, 2026 | News
Proof-of-concept SHEPHERD study will assess SUL-238’s effects on mitochondrial function in patients with Parkinson’s disease Ankara, Türkiye, June 08, 2026 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, announced today that the...
by Raymond Tel | Mar 17, 2026 | News
ANKARA, Türkiye, March 16, 2026 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, announced today that it has received approval in the Netherlands from the BEBO Foundation for the Assessment of Ethics of Biomedical...
by Raymond Tel | Dec 2, 2025 | News
GEN Announces New Positive Phase 1 Trial Data of the Investigational Drug SUL-238 for Alzheimer’s and Other Neurodegenerative Diseases. Ankara, Türkiye, December 02, 2025 – GEN Pharmaceuticals (GENIL.IS), Türkiye’s leading specialty pharmaceutical company, has...
by Raymond Tel | Aug 25, 2025 | News
There is another medical need application of the SUL-compound group with SUL-150, a compound closely related to SUL-238. Recently, a new scientific paper has been published in The International Journal of Molecular Sciences about the potential of SUL-150 as treatment...
